多发性骨髓瘤嵌合抗原受体T细胞与双特异性抗体治疗期间感染预防建议
嵌合抗原受体T细胞(CAR T)与双特异性抗体治疗在多发性骨髓瘤(MM)中疗效显著但严重感染风险高。来自COMMIT的专家组制定共识建议,用于感染监测与预防,直至前瞻性临床试验数据可用。
要点
- CAR T与双特异性抗体治疗MM相关严重感染风险显著。
- 感染风险因素包括低丙种球蛋白血症、中性粒细胞减少等。
- COMMIT专家组制定共识建议以监测和预防感染。
核心结论
- CAR T与双特异性抗体治疗MM疗效前所未有,但严重感染风险显著。
- COMMIT专家组制定共识建议以减轻感染风险,直至前瞻性临床试验数据可用。
研究设计与样本
- 来自Academic Consortium to Overcome Multiple Myeloma through Innovative Trials(COMMIT)的经验丰富研究者专家组制定共识建议。
主要发现
- CAR T与双特异性抗体治疗在重度预处理MM患者中显示前所未有的疗效。
- 严重感染风险与低丙种球蛋白血症、中性粒细胞减少、淋巴细胞减少、T细胞耗竭、细胞因子释放综合征和免疫效应细胞相关神经毒性综合征等因素相关。
临床怎么用
- 原文未据此给出具体推荐条款。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T-cell exhaustion, cytokine-release syndrome and immune-effector cell-associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T-cell and bispecific antibody therapies in MM patients.
引用
- Mohan M, Chakraborty R, Bal S, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023. PMID: 37287117. doi:10.1111/bjh.18909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。